Literature DB >> 14688102

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Soe Soe1, Michael Theisen, Christian Roussilhon, Khin-Saw Aye, Pierre Druilhe.   

Abstract

We performed a longitudinal clinical and parasitological follow-up study in OoDo, a village in southeast Asia in which malaria is hyperendemic, in order to assess the association between protection against malaria attacks and antibodies to three currently evaluated vaccine candidates, merozoite surface protein 1 (MSP1), MSP3, and the 220-kDa glutamate-rich protein (GLURP) from Plasmodium falciparum. Our results showed that the levels of cytophilic immunoglobulin G3 (IgG3) antibodies against conserved regions of MSP3 and GLURP were significantly correlated with protection against clinical P. falciparum malaria. In contrast, the levels of noncytophilic IgG4 antibodies against GLURP increased with the number of malaria attacks. Furthermore, we observed a complementary effect of the MSP3- and GLURP-specific IgG3 antibodies in relation to malaria protection. In the individuals that did not respond to one of the antigens, a strong response to the other antigen was consistently detected and was associated with protection, suggesting that induction of antibodies against both MSP3 and GLURP could be important for the development of protective immunity. The complementarity of the responses to the two main targets of antibody-dependent cellular inhibition identified to date provides the first rational basis for combining these two antigens in a hybrid vaccine formulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688102      PMCID: PMC343946          DOI: 10.1128/IAI.72.1.247-252.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2.

Authors:  Francis M Ndungu; Peter C Bull; Amanda Ross; Brett S Lowe; Ephantus Kabiru; Kevin Marsh
Journal:  Parasite Immunol       Date:  2002-02       Impact factor: 2.280

2.  Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum.

Authors:  D R Cavanagh; C Dobaño; I M Elhassan; K Marsh; A Elhassan; L Hviid; E A Khalil; T G Theander; D E Arnot; J S McBride
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Antibodies in falciparum malaria: what matters most, quantity or quality?

Authors:  H Bouharoun-Tayoun; P Druilhe
Journal:  Mem Inst Oswaldo Cruz       Date:  1992       Impact factor: 2.743

4.  The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.

Authors:  M Theisen; S Soe; C Oeuvray; A W Thomas; J Vuust; S Danielsen; S Jepsen; P Druilhe
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

5.  IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.

Authors:  R R Taylor; S J Allen; B M Greenwood; E M Riley
Journal:  Am J Trop Med Hyg       Date:  1998-04       Impact factor: 2.345

6.  Short report: entomologic inoculation rates and Plasmodium falciparum malaria prevalence in Africa.

Authors:  J C Beier; G F Killeen; J I Githure
Journal:  Am J Trop Med Hyg       Date:  1999-07       Impact factor: 2.345

7.  Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar.

Authors:  C Roussilhon; J L Pérignon; P Druilhe
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.184

8.  A hypothesis about the chronicity of malaria infection.

Authors:  P Druilhe; J L Pérignon
Journal:  Parasitol Today       Date:  1997-09

9.  Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro.

Authors:  F Lunel; P Druilhe
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

10.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  74 in total

1.  Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Authors:  Maryam Imam; Yengkhom Sangeeta Devi; Akhilesh K Verma; Virander Singh Chauhan
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

4.  Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria.

Authors:  J Eric Tongren; Christopher J Drakeley; Suzanna L R McDonald; Hugh G Reyburn; Alphaxard Manjurano; Watoky M M Nkya; Martha M Lemnge; Channe D Gowda; Jim E Todd; Patrick H Corran; Eleanor M Riley
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

6.  Identification of target proteins of clinical immunity to Plasmodium falciparum in a region of low malaria transmission.

Authors:  Hirokazu Sakamoto; Satoru Takeo; Eizo Takashima; Kazutoyo Miura; Bernard N Kanoi; Takamasa Kaneko; Eun-Taek Han; Mayumi Tachibana; Kazuhiro Matsuoka; Jetsumon Sattabongkot; Rachanee Udomsangpetch; Tomoko Ishino; Takafumi Tsuboi
Journal:  Parasitol Int       Date:  2017-12-05       Impact factor: 2.230

7.  Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.

Authors:  Christian Roussilhon; Philippe Brasseur; Patrice Agnamey; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

8.  Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.

Authors:  Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

9.  Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.

Authors:  John P A Lusingu; Samwel Gesase; Salum Msham; Filbert Francis; Martha Lemnge; Misago Seth; Samwel Sembuche; Acleus Rutta; Daniel Minja; Method D Segeja; Samuel Bosomprah; Simon Cousens; Ramadhani Noor; Roma Chilengi; Pierre Druilhe
Journal:  Malar J       Date:  2009-07-17       Impact factor: 2.979

10.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.